Yohimbine

PreclinicalSmall molecule

NNational Institute of Mental Health (NIMH)

Yohimbine is one of 103 small molecule programs targeting Cognition. It is currently in Preclinical.

Indications

Total Trials

Active Trials

102

Competitors

Pipeline

Status by Indication[3][1]

Indication

CognitionActive, not recruiting

Major Depressive DisorderActive, not recruiting

Intrusive MemoriesCompleted

Pain PerceptionUnknown status

CognitionPreclinical

Active, not recruiting

Major Depressive DisorderPreclinical

Active, not recruiting

Intrusive MemoriesPreclinical

Completed

Pain PerceptionPreclinical

Unknown status

Competition

Competitive Landscape

115 competitors in Major Depressive Disorder

#DrugCompanyPhaseTrials

Vraylar

AbbVie

Approved

6 2

Zoloft

VViatris Specialty LLC

Approved

15 3

Effexor

WWyeth-Lederle Vaccines

Approved

8 4

Ulotaront

IIntra-Cellular Therapies, Inc.

Approved

6 5

Valcyte

EEngelhard Arzneimittel GmbH & Co.KG

Approved

—6

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

12 7

Ketalar

Boehringer Ingelheim

Phase 3

5 8

Lithobid

SSolvay Pharmaceuticals

Phase 3

1 9

Clozaril

LLife Extension Foundation Inc.

Phase 3

1 10

Psilocybin

COMPASS Pathways

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

AIN3 trials

The Effect of Yohimbine on Cocaine Cue Reactivity

Completed·MMedical University of South Carolina·Phase 2·NCT00535002·112 enrolled

Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine

Completed·WWalter Ritter GmbH & Co·Phase 4·NCT00975325·42 enrolled

Brain Receptors in Sympathetic Nervous System Regulation

Completed·NNational Institute of Mental Health (NIMH)··NCT00029627·200 enrolled

Orthostatic Hypotension2 trials

Effects of Melatonin to Reduce Nocturnal Hypertension in Patients With Neurogenic Orthostatic Hypotension

Terminated·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 1·NCT02963181·10 enrolled

Treatment of Orthostatic Hypotension in Autonomic Failure

Completed·VVanderbilt University·Phase 1·NCT00223691·389 enrolled

Post-Traumatic Stress Disorder, PTSD1 trial

Prolonged Exposure for Post Traumatic Stress Disorder (PTSD) With/Without Yohimbine

Completed·VVA Office of Research and Development·Phase 2·NCT01031979·26 enrolled

Attention1 trial

The Role of Stress Neuromodulators in Decision Making Under Risk and Selective Attention to Threat

Completed·—·N/A·NCT04359147·167 enrolled

Stress1 trial

Effects of Stress and Drug-cue Exposure (SCM)

Completed·WWayne State University·Phase 1·NCT03154567·12 enrolled

8 more indications

Type 2 Diabetes1 trial

Randomized Study of Yohimbine Treatment for Type 2 Diabetes Patients Carrying a Specific Genetic Risk Variant

Completed·—·Phase 2·NCT01593215·50 enrolled

Unknown status·TTel-Aviv Sourasky Medical Center·N/A·NCT01621620·20 enrolled

PET1 trial

[11C]Yohimbine PET Study of alpha2-AR

Completed·HHospices Civils de Lyon·Phase 1·NCT03520543·16 enrolled

Intrusive Memories1 trial

Influence of the Noradrenergic System on the Formation of Intrusive Memories

Completed·—·N/A·NCT02541071·118 enrolled

Major Depressive Disorder1 trial

Noradrenergic Activity, Cognition and Major Depressive Disorder

Completed·—·N/A·NCT02470026·131 enrolled

Unspecified1 trial

Effect of Yohimbine on Colon Transit

Completed·MMayo Clinic·Phase 1/2·NCT00217048·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Yohimbine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Yohimbine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Yohimbine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Mental Health (NIMH) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNational Institute of Mental Health (NIMH)

Yohimbine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

AIN3 trials

Orthostatic Hypotension2 trials

Post-Traumatic Stress Disorder, PTSD1 trial

Attention1 trial

Stress1 trial

Type 2 Diabetes1 trial

Cognition1 trial

Alcohol1 trial

Pain Perception1 trial

PET1 trial

Intrusive Memories1 trial

Major Depressive Disorder1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News